Fresenius, Polpharma Biologics Ink Deal to Commercialize Vedolizumab Biosimilar
Fresenius Kabi is expanding its biopharmaceutical portfolio through a new global licensing agreement with Polpharma Biologics S.A., securing exclusive rights to commercialize the…
Read More...
Read More...
